LeMaitre Vascular Inc (NASDAQ:LMAT) has been assigned an average rating of “Hold” from the ten brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $34.67.
LMAT has been the topic of several research reports. Barrington Research upgraded shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Monday, October 8th. ValuEngine lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, October 6th. Canaccord Genuity dropped their price objective on shares of LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating on the stock in a research note on Monday, October 8th. BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. Finally, Lake Street Capital lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 5th.
LMAT traded down $0.11 on Friday, hitting $28.05. 110,200 shares of the company’s stock were exchanged, compared to its average volume of 150,420. The firm has a market cap of $555.81 million, a price-to-earnings ratio of 32.76, a price-to-earnings-growth ratio of 2.33 and a beta of 0.63. LeMaitre Vascular has a twelve month low of $26.45 and a twelve month high of $41.28.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, hitting the consensus estimate of $0.21. The firm had revenue of $24.17 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a net margin of 20.52% and a return on equity of 18.49%. Equities analysts anticipate that LeMaitre Vascular will post 1.03 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Shareholders of record on Tuesday, November 20th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.28 annualized dividend and a dividend yield of 1.00%. LeMaitre Vascular’s payout ratio is currently 32.56%.
In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 39,820 shares of the firm’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $37.34, for a total value of $1,486,878.80. Following the sale, the chairman now owns 3,085,291 shares in the company, valued at $115,204,765.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 21,005 shares of the firm’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $35.72, for a total transaction of $750,298.60. Following the completion of the sale, the director now owns 5,373 shares in the company, valued at approximately $191,923.56. The disclosure for this sale can be found here. Insiders sold 97,506 shares of company stock worth $3,608,759 in the last 90 days. 20.30% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in the business. Swiss National Bank increased its stake in shares of LeMaitre Vascular by 6.8% in the first quarter. Swiss National Bank now owns 26,600 shares of the medical instruments supplier’s stock valued at $964,000 after purchasing an additional 1,700 shares during the period. Polen Capital Management LLC increased its stake in shares of LeMaitre Vascular by 24.5% in the second quarter. Polen Capital Management LLC now owns 9,849 shares of the medical instruments supplier’s stock valued at $330,000 after purchasing an additional 1,941 shares during the period. Strs Ohio increased its stake in shares of LeMaitre Vascular by 9.5% in the second quarter. Strs Ohio now owns 23,000 shares of the medical instruments supplier’s stock valued at $770,000 after purchasing an additional 2,000 shares during the period. Rhumbline Advisers increased its stake in shares of LeMaitre Vascular by 3.5% in the second quarter. Rhumbline Advisers now owns 60,205 shares of the medical instruments supplier’s stock valued at $2,016,000 after purchasing an additional 2,015 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of LeMaitre Vascular by 7.1% in the second quarter. Legal & General Group Plc now owns 30,425 shares of the medical instruments supplier’s stock valued at $1,021,000 after acquiring an additional 2,018 shares in the last quarter. Institutional investors own 79.75% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Further Reading: Moving Average (MA)
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.